Published Technical Disclosure Archive

Specialized Anti-mycobacterial Solutions for Niche Environments

Publication ID: 24-11857521_0004_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized Anti-mycobacterial Solutions for Niche Environments,” Published Technical Disclosure No. 24-11857521_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857521_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,521.

Summary of the Inventive Concept

Adapting anti-mycobacterial drugs for specific, high-need markets and unique operational environments, such as high-altitude regions, disaster relief, high-security facilities, and extreme weather conditions.

Background and Problem Solved

The original patent disclosed anti-mycobacterial drugs with a lengthy treatment regimen. This inventive concept addresses the limitations of the original patent by providing specialized solutions for niche environments, where traditional treatment regimens may not be effective or practical.

Detailed Description of the Inventive Concept

The new inventive concept comprises four specialized variations: 1) a method for treating tuberculosis in high-altitude regions, 2) a system for disaster relief, 3) a formulation for high-security facilities, and 4) a device for detecting mycobacterial infections in extreme weather conditions. Each variation leverages the original oligo(carbamoylated guanidine) (OCG) structure, with tailored modifications to address the unique challenges of these niche environments.

Novelty and Inventive Step

The new claims introduce novel combinations of the OCG structure with specialized components and operational environments, providing a non-obvious solution for treating mycobacterial infections in these niche markets.

Alternative Embodiments and Variations

Alternative embodiments could include adapting the OCG structure for use in other extreme environments, such as space exploration or deep-sea operations. Variations could also include different formulations or delivery methods for the OCG, such as oral or topical administration.

Potential Commercial Applications and Market

The specialized anti-mycobacterial solutions have significant commercial potential in the global healthcare and biotechnology markets, particularly in regions with high incidence of tuberculosis or areas prone to natural disasters. Target industries include pharmaceutical companies, disaster relief organizations, and high-security facility operators.

CPC Classifications

SectionClassGroup
A A61 A61K31/17
A A61 A61K31/133
A A61 A61K31/277
A A61 A61K31/4409
A A61 A61K31/47
A A61 A61K31/496
A A61 A61K31/498
A A61 A61K31/4965
A A61 A61K31/5377
A A61 A61P31/06
C C07 C07C279/12
C C07 C07D295/215
C C08 C08G65/00
C C08 C08G71/02
C C07 C07C2601/16

Field of Art

Pharmaceutical chemistry with specialization in anti-mycobacterial drug development, focusing on synthetic organic chemistry, drug formulation, and targeted therapeutic interventions for infectious diseases

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degree in pharmaceutical sciences or organic chemistry, experienced in drug design, molecular modification techniques, and understanding structure-activity relationships for antimicrobial compounds

Obviousness Rationale

A PHOSITA would recognize that the published technical disclosure represents predictable variations of the source patent's oligo(carbamoylated guanidine) structure, applying standard pharmaceutical engineering techniques to adapt the core molecular design for specific environmental and operational contexts. The variations demonstrate routine optimization of drug delivery and application strategies using known methodological approaches in pharmaceutical development. These modifications represent incremental adaptations that would be readily conceived by a skilled practitioner familiar with drug design and infectious disease treatment challenges.

Obvious Combinations & Variations

Source Patent Element
Oligo(carbamoylated guanidine) with variable structural parameters (n = 3-50, configurable X and Y substituents)
PTD Variation
Specialized delivery methods including UAV-based administration and portable disaster relief containers
Obviousness Reasoning
Standard pharmaceutical engineering practice involves developing alternative delivery mechanisms for existing drug structures, representing a predictable solution for expanding treatment accessibility
Source Patent Element
Base molecular structure targeting mycobacterial infections
PTD Variation
Environment-specific formulations for high-altitude, extreme weather, and controlled facility applications
Obviousness Reasoning
Adapting pharmaceutical compositions for specific environmental conditions represents a routine design optimization process within pharmaceutical development
Source Patent Element
Modular chemical structure with configurable substituents
PTD Variation
Sensor-integrated detection and dispensing systems for mycobacterial infections
Obviousness Reasoning
Integrating diagnostic and therapeutic technologies is a known approach in medical device development, representing an obvious combination of existing technological capabilities
Source Patent Element
Anti-mycobacterial drug composition with variable structural parameters
PTD Variation
Alternative administration routes and formulation strategies for remote or challenging environments
Obviousness Reasoning
Exploring multiple administration methods is a standard pharmaceutical research approach for expanding drug utility and patient accessibility
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed herein would be considered obvious to a person having ordinary skill in the art at the time of invention, as they represent predictable extensions of the foundational anti-mycobacterial drug composition disclosed in US Patent 11857521, employing routine pharmaceutical engineering techniques to adapt the core molecular structure for specialized environmental and operational contexts.

Original Patent Information

Patent NumberUS 11,857,521
TitleAnti-mycobacterial drugs
Assignee(s)The Florida International University Board of Trustees